Effects of Pharmacotherapy for the Treatment of Obesity in an Urban, Safety-Net Population

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Nov 30

PMID 38034269

Authors

Eric K Kim

Nancy K Hills

Zoe Cheng

Caroline Tucker

Maria Gutierrez

Diana Alba

Elizabeth Murphy

Sarah Kim

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the effect of common weight loss pharmacotherapies among low-income, racially diverse adult patients at an urban safety-net weight management clinic.

Methods: Our retrospective review from 2015 to 2019 examined patients who took either GLP-1 analog (GL) or phentermine/topiramate (PT) for ≥90 days and patients who exclusively pursued non-pharmacologic treatment for comparison. Changes in weight, blood pressure, and hemoglobin A1c at 1-year follow-up were reported.

Results: We analyzed 22 GL and 26 PT patients and included 40 patients who pursued only lifestyle modifications (LM). All three groups achieved significant weight loss at one year: GL -3.69 (interquartile range (IQR): -11.0, -1.77) kg (p=0.0004), PT -7.01 (IQR: -13.4, -1.45) kg (p<0.001), and LM -3.01 (IQR: -6.81, 1.13) kg (p=0.005). There was no significant difference in the median weight loss (p=0.11) between the three groups. We observed no significant changes in systolic blood pressure but saw a significant change of -0.75 in hemoglobin A1c (IQR: -1.35, -0.25) (p=0.01) among patients with diabetes in the GL group.

Conclusions: Our real-world applications of GLP-1 and phentermine/topiramate suggest that both are effective weight loss medication regimens in low-socioeconomic status patients.

References

Ryan D, Yockey S . Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr Obes Rep. 2017; 6(2):187-194. PMC: 5497590. DOI: 10.1007/s13679-017-0262-y. View

Davidson J, Orsted D, Campos C . Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials. Diabetes Obes Metab. 2016; 18(7):725-8. DOI: 10.1111/dom.12653. View

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M . A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373(1):11-22. DOI: 10.1056/NEJMoa1411892. View

Katzmarzyk P, Martin C, Newton Jr R, Apolzan J, Arnold C, Davis T . Weight Loss in Underserved Patients - A Cluster-Randomized Trial. N Engl J Med. 2020; 383(10):909-918. PMC: 7493523. DOI: 10.1056/NEJMoa2007448. View

Larson N, Story M, Nelson M . Neighborhood environments: disparities in access to healthy foods in the U.S. Am J Prev Med. 2008; 36(1):74-81. DOI: 10.1016/j.amepre.2008.09.025. View

Wang Y, Beydoun M . The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007; 29:6-28. DOI: 10.1093/epirev/mxm007. View

Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M . Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009; 374(9701):1606-16. DOI: 10.1016/S0140-6736(09)61375-1. View

Filippatos T, Panagiotopoulou T, Elisaf M . Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2015; 11(3-4):202-30. PMC: 5397288. DOI: 10.1900/RDS.2014.11.202. View

ONeil P, Garvey W, Gonzalez-Campoy J, Mora P, Ortiz R, Guerrero G . EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016; 22(11):1277-1287. DOI: 10.4158/EP151181.OR. View

10.

Jensen M, Ryan D, Apovian C, Ard J, Comuzzie A, Donato K . 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2013; 129(25 Suppl 2):S102-38. PMC: 5819889. DOI: 10.1161/01.cir.0000437739.71477.ee. View

11.

Heymsfield S, Wadden T . Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017; 376(3):254-266. DOI: 10.1056/NEJMra1514009. View

12.

Mayer-Davis E, DAntonio A, Smith S, Kirkner G, Martin S, Parra-Medina D . Pounds off with empowerment (POWER): a clinical trial of weight management strategies for black and white adults with diabetes who live in medically underserved rural communities. Am J Public Health. 2004; 94(10):1736-42. PMC: 1448527. DOI: 10.2105/ajph.94.10.1736. View

13.

Ogden C, Carroll M, Fakhouri T, Hales C, Fryar C, Li X . Prevalence of Obesity Among Youths by Household Income and Education Level of Head of Household - United States 2011-2014. MMWR Morb Mortal Wkly Rep. 2018; 67(6):186-189. PMC: 5815488. DOI: 10.15585/mmwr.mm6706a3. View

14.

Saxon D, Chaussee E, Juarez-Colunga E, Tsai A, Iwamoto S, Speer R . A Toolbox Approach to Obesity Treatment in Urban Safety-Net Primary Care Clinics: a Pragmatic Clinical Trial. J Gen Intern Med. 2019; 34(11):2405-2413. PMC: 6848318. DOI: 10.1007/s11606-019-05222-0. View

15.

Lovasi G, Hutson M, Guerra M, Neckerman K . Built environments and obesity in disadvantaged populations. Epidemiol Rev. 2009; 31:7-20. DOI: 10.1093/epirev/mxp005. View